Primary Open-Angle Glaucoma

Aerie and Santen have entered an agreement for Rhopressa and Rocklatan in Europe, China, India, Commonwealth of Independent State countries, parts of Latin America and Oceanic countries, according to a company press release.

NEW ORLEANS — The majority of patients who underwent laser trabeculoplasty or iStent implantation saw no tangible reduction in their health care burden, according to a study presented at the American Academy of Ophthalmology meeting.

The FDA has issued an investigational device exemption for a clinical study to evaluate the safety and effectiveness of a higher-volume Omni device for canal viscodilation in adults with primary open-angle glaucoma.

Alcon intends to acquire Ivantis, the developer and manufacturer of the Hydrus microstent, according to a company press release.

Patients with primary open-angle glaucoma who undergo cataract surgery have an opportunity to have both phacoemulsification with IOL implantation and a glaucoma procedure performed at the same sitting.

The U.S. Preventive Services Task Force has issued draft recommendations that state there is not enough evidence to assess the balance of benefits and harms of screening some adults for primary open-angle glaucoma and impaired visual acuity.

We are extremely fortunate to have a number of efficacious and relatively safe medical therapies to choose from when treating our patients with ocular hypertension and glaucoma.

Presentations from the American Society of Cataract and Refractive Surgery meeting led recent glaucoma coverage on Healio/OSN.

OTX-TIC, a hydrogel-based implant that delivers travoprost, demonstrated similar IOP control compared with topical therapy, according to a study.

Alcon has signed an agreement to receive U.S. commercialization rights to Simbrinza from Novartis, according to a press release.